Clinical Guides
Hyperparathyroidism
A clinically focused guide to recognising and classifying hyperparathyroidism, interpreting calcium and parathyroid hormone correctly, excluding familial hypocalciuric hypercalcaemia, and selecting surgery or monitored medical care in Indian practice.
MedNext Academy | 13 min read
Hyperparathyroidism
A clinically focused guide to recognising and classifying hyperparathyroidism, interpreting calcium and parathyroid hormone correctly, excluding familial hypocalciuric hypercalcaemia, and selecting surgery or monitored medical care in Indian practice.
Summary
Hyperparathyroidism is excessive or inappropriate parathyroid hormone (PTH) activity for the prevailing calcium concentration. Primary hyperparathyroidism is usually a sporadic parathyroid adenoma and is diagnosed biochemically: repeated hypercalcaemia with a raised or inappropriately non-suppressed PTH, after excluding important mimics. Secondary hyperparathyroidism is an appropriate PTH response to chronic stimuli such as vitamin D deficiency, chronic kidney disease (CKD), malabsorption or low calcium intake, usually with normal or low calcium. Tertiary hyperparathyroidism is autonomous secretion after prolonged secondary stimulation, most often in advanced CKD, and may produce hypercalcaemia. These entities must not be collapsed into one treatment pathway.
Interpret calcium before ordering localisation. Confirm the laboratory unit and reference range, repeat albumin-adjusted calcium, consider ionised calcium when albumin correction is unreliable or results conflict, and measure PTH concurrently. Assess renal function, phosphate, 25-hydroxyvitamin D, medicines, urine calcium, kidney stones and skeletal disease. Familial hypocalciuric hypercalcaemia (FHH) is a crucial alternative because parathyroidectomy usually does not correct it.
Parathyroidectomy is the only definitive treatment for sporadic primary hyperparathyroidism and is recommended for symptomatic or guideline-defined end-organ or biochemical disease. Imaging identifies operative anatomy only after a surgical indication exists; it neither establishes nor excludes the diagnosis. Patients who do not undergo surgery need defined calcium, renal and bone surveillance, correction of contributory deficiency, and selective medical therapy. Severe symptomatic hypercalcaemia is an emergency requiring monitored fluid resuscitation and specialist treatment.
How Common Is It?
Primary hyperparathyroidism is a common cause of outpatient hypercalcaemia, but its recorded frequency depends on biochemical screening, assay quality, age, sex and access to care. It is diagnosed more often in women and older adults in screened populations. Contemporary cohorts include many people without the classical combination of stones, bones, abdominal symptoms and neuropsychiatric disturbance, yet apparently mild disease may still involve osteoporosis, vertebral fracture or occult nephrolithiasis. Estimates from North American or European laboratory systems cannot be presented as a current national rate for India.
Indian patients may be detected later because calcium is not measured routinely, albumin is not available with the same specimen, vitamin D deficiency complicates interpretation, or specialist imaging and surgery require travel. Tertiary and secondary hyperparathyroidism also vary with the CKD population, dialysis practice, phosphate control and access to transplantation. Hospital series therefore describe referral case mix rather than community prevalence.
A useful local audit records how many raised calcium results are repeated, whether calcium and PTH are sampled together, whether vitamin D and renal function are checked, and how often stone or bone disease is identified. It should separate primary, secondary and tertiary disease and track time from biochemical suspicion to endocrine and surgical assessment. Evidence on long-term cardiovascular or cognitive benefit from operating on otherwise mild primary disease remains less certain than evidence for correcting hypercalcaemia and protecting established skeletal or renal indications.
Risk Factors
Most primary hyperparathyroidism is sporadic. Risk increases with age, female sex and previous therapeutic neck irradiation. Lithium can shift calcium sensing and cause or unmask hyperparathyroid biochemistry; thiazides can raise calcium and complicate assessment. Multiple endocrine neoplasia types 1 and 2A, hyperparathyroidism-jaw tumour syndrome and familial isolated hyperparathyroidism should be considered when disease is young-onset, multiglandular, recurrent, associated with another endocrine tumour or clustered in a family. A detailed pedigree is more useful than indiscriminate genetic testing.
Secondary hyperparathyroidism is promoted by CKD, vitamin D deficiency, malabsorption, bariatric surgery, anticonvulsant-related vitamin D disturbance and sustained low calcium intake. In CKD, falling calcitriol, phosphate retention and altered calcium sensing contribute; a single raised PTH should be interpreted against CKD stage, serial trend, calcium, phosphate and modifiable factors. Tertiary disease usually follows prolonged severe secondary hyperparathyroidism in dialysis or after transplantation.
Complication risk is not identical to disease risk. Higher calcium, reduced estimated glomerular filtration rate, kidney stones, hypercalciuria, low bone density and vertebral fracture increase the case for intervention. Dehydration, immobilisation and interacting medicines may abruptly worsen hypercalcaemia. In India, limited dietary diversity, over-the-counter calcium or vitamin D, unregulated supplements and delayed CKD follow-up should be asked about without assuming causation. Do not label vitamin D deficiency as the explanation for a non-suppressed PTH until calcium status and renal function have been interpreted together.
Diagnosis
History
Ask about renal colic, haematuria, fractures, height loss, bone pain, proximal weakness, constipation, nausea, thirst, polyuria, mood or cognitive change and prior high calcium. Record kidney disease, malabsorption, bariatric surgery, neck irradiation, pregnancy, family hypercalcaemia, endocrine tumours and medicines including lithium, thiazides, calcium, vitamin D and traditional preparations. Symptoms are nonspecific; their presence supports assessment but does not replace biochemical diagnosis.
Examination
Assess hydration, blood pressure, cognition, muscle strength, bony tenderness, deformity and signs of CKD or endocrine syndromes. Palpable parathyroid lesions are unusual and a neck mass needs broader evaluation. Look for consequences of severe hypercalcaemia, including reduced consciousness, arrhythmia and volume depletion. Examination may be normal in important disease.
Investigations
Repeat albumin-adjusted calcium with a concurrent intact PTH. A PTH within the numerical reference interval is inappropriate when calcium is high because normal physiology should suppress it. Check phosphate, creatinine and eGFR, magnesium, alkaline phosphatase and 25-hydroxyvitamin D. Use ionised calcium when albumin correction is unreliable or normocalcaemic primary disease is considered. Obtain 24-hour urine calcium and calculate the calcium-to-creatinine clearance ratio when FHH is plausible, recognising overlap and distortion by CKD, vitamin D deficiency, thiazides or low calcium intake. Assess DXA at lumbar spine, hip and distal one-third radius, vertebral imaging when indicated, and renal imaging for stones or nephrocalcinosis. Localisation imaging follows, never precedes, a decision for surgery.
Differential Diagnosis
FHH is the high-stakes mimic of primary hyperparathyroidism. It usually causes lifelong mild hypercalcaemia, non-suppressed PTH, relative hypocalciuria and family history, although de novo variants occur. A calcium-to-creatinine clearance ratio below 0.01 supports FHH and above 0.02 favours primary disease, but results overlap; vitamin D deficiency, low intake, thiazides and renal impairment can falsely lower urine calcium. Repeat interpretable testing and CASR-pathway genetic assessment may be needed before surgery. Parathyroidectomy is generally ineffective in FHH.
PTH-independent hypercalcaemia suppresses PTH and redirects evaluation toward malignancy, granulomatous disease, thyrotoxicosis, vitamin A or D toxicity, immobilisation, adrenal insufficiency and other causes. A high calcium with a genuinely suppressed PTH is not primary hyperparathyroidism. Laboratory error, dehydration and albumin disturbance should be excluded with repeat or ionised calcium. Biotin can interfere with some immunoassays; ask about supplements and follow the laboratory's washout advice.
Secondary hyperparathyroidism has a stimulus: CKD, vitamin D deficiency, malabsorption or low calcium availability. Normocalcaemic primary hyperparathyroidism is a diagnosis of exclusion requiring persistently normal total and ionised calcium with repeatedly elevated PTH after secondary causes and medicines are addressed. Tertiary disease occurs after longstanding secondary stimulation and must be distinguished from a coincidental adenoma. In CKD, apply serial biochemical interpretation and CKD-mineral and bone disorder guidance rather than importing primary-disease thresholds uncritically.
Management
Confirm the phenotype and complications before treatment. Replace vitamin D cautiously when deficient and ensure appropriate calcium intake rather than severe restriction, while monitoring calcium and urine calcium. Review lithium or thiazide with the prescriber; do not stop an essential medicine abruptly. Encourage hydration and mobility where appropriate, address falls and fracture risk, and manage CKD-mineral and bone disorder through renal services. Severe symptomatic hypercalcaemia requires emergency assessment, isotonic fluid guided by cardiac and renal status, treatment of the cause and specialist-directed antiresorptive or calcimimetic therapy.
Offer expert parathyroid surgery assessment for symptomatic primary disease or objective renal, skeletal, age or calcium criteria. The Fifth International Workshop identifies serum calcium more than 1 mg/dL above the upper limit, vertebral fracture or T-score at or below -2.5, eGFR or creatinine clearance below 60 mL/min, nephrolithiasis or nephrocalcinosis, hypercalciuria above sex-specific thresholds, or age below 50 years as indications in otherwise asymptomatic patients. current guidelines also recommends referral for symptoms, end-organ disease or adjusted calcium at least 2.85 mmol/L. Use the applicable guideline and multidisciplinary judgement rather than mixing thresholds invisibly.
When surgery is declined, contraindicated or deferred, establish surveillance for calcium, renal function, stone symptoms and bone density. Cinacalcet lowers calcium but does not reliably improve bone density; antiresorptive treatment may improve bone density but is not a definitive calcium cure. Select therapy for the actual goal. Deterioration, a new stone, fracture, falling renal function or rising calcium should reopen surgical discussion.
Prescribing Information
Cinacalcet is a calcimimetic that increases calcium-sensing receptor sensitivity and can reduce serum calcium in primary hyperparathyroidism when surgery is unsuitable, unsuccessful or declined. current guidelines links consideration to persistent adjusted calcium thresholds and symptoms, but local product information, renal and hepatic status, interactions and specialist oversight govern use. Nausea is common; hypocalcaemia can be dangerous. Measure calcium after initiation and dose change, and explain symptoms such as paraesthesia, cramps or seizure. A lower calcium does not prove skeletal or renal risk has been removed.
Bisphosphonates may be selected to improve bone mineral density in primary disease when fracture risk is important, but they should not be prescribed solely as a long-term strategy to lower serum calcium. Check renal function, dental risk, vitamin D and calcium balance, administration requirements and pregnancy considerations. Denosumab is specialist-led and stopping it without a transition plan can cause rebound vertebral fractures. Calcium intake should generally meet nutritional requirements; extreme restriction may further stimulate PTH. Vitamin D replacement needs planned calcium monitoring rather than avoidance or high-dose empirical treatment.
After parathyroidectomy, monitor calcium and symptoms. Hungry bone syndrome can produce prolonged hypocalcaemia, especially with severe bone disease or very high turnover, and may require calcium and active vitamin D under a protocol. In CKD, calcimimetics, vitamin D analogues, phosphate binders and surgery have different indications and risks; prescriptions follow nephrology guidance. This educational draft deliberately avoids a universal dosing schedule because formulations, laboratory access, kidney function, pregnancy and institutional pathways alter safe use.
When to Refer
Refer confirmed or strongly suspected primary hyperparathyroidism to endocrinology or an experienced clinician for phenotype confirmation, complication assessment and treatment planning. Surgical referral should go to a parathyroid surgeon when guideline criteria, symptoms or patient preference support definitive treatment. Young age, multigland disease, recurrence, a family history or associated pituitary, pancreatic, adrenal, thyroid, jaw or renal lesions warrants genetic or endocrine-syndrome evaluation before an operation that assumes a solitary adenoma. Pregnancy requires prompt endocrine, obstetric and surgical discussion because maternal hypercalcaemia threatens both mother and fetus.
Seek renal input for advanced CKD, dialysis, transplantation, persistent phosphate disturbance or suspected tertiary hyperparathyroidism. Bone specialists may help when fracture, severe osteoporosis or treatment complexity persists. Urology is appropriate for obstruction, recurrent stones or procedural stone care. Refer urgently for marked or rapidly rising calcium with dehydration, vomiting, confusion, weakness, arrhythmia, acute kidney injury or inability to maintain oral intake. Stabilisation and transfer should not wait for localisation imaging.
A useful referral includes repeated calcium with albumin or ionised calcium, paired PTH, renal function, phosphate, magnesium, vitamin D, medicine list, urine calcium data with collection quality, DXA sites, vertebral and renal imaging, previous neck surgery and family history. State which diagnostic uncertainty remains, particularly FHH. In resource-limited Indian settings, referral should identify the centre capable of both endocrine interpretation and experienced parathyroid surgery rather than ordering multiple disconnected scans.
Red Flags
Confusion, reduced consciousness, profound weakness, persistent vomiting, severe dehydration, oliguria, acute kidney injury, syncope or arrhythmia with hypercalcaemia requires emergency care. The absolute calcium value matters, but rate of rise, symptoms, renal function and comorbidity also determine risk. Confirm units: 1 mmol/L calcium is approximately 4 mg/dL, and a misplaced unit can cause a catastrophic decision. Obtain ECG, repeat calcium, electrolytes and renal function while resuscitating according to physiology. Heart or kidney failure requires smaller reassessed fluid aliquots and senior support.
Do not operate on a scan. A sestamibi, ultrasound or 4D CT finding cannot diagnose primary hyperparathyroidism and an apparently negative scan does not exclude biochemical disease. Conversely, incidental tracer uptake or a neck nodule may mislead when calcium and PTH physiology does not fit. FHH not considered before surgery, especially in a young person with mild stable hypercalcaemia and low urine calcium, is a preventable harm.
Other red flags are fracture, vertebral collapse, bilateral or recurrent stones, progressive eGFR loss, very high alkaline phosphatase, pancreatitis with hypercalcaemia, pregnancy, childhood disease and possible MEN syndrome. After surgery, perioral tingling, carpopedal spasm, stridor, seizure or QT prolongation suggests clinically important hypocalcaemia. Neck swelling, airway difficulty or voice change requires immediate surgical assessment. Patients has been reviewed by the MedNext Clinical Team need explicit advice about hydration, medicines and symptoms that should trigger urgent reassessment.
Indian Clinical Context
Indian laboratories report calcium in mg/dL or mmol/L and use different albumin assays and reference intervals. Record the unit, reference range and sampling conditions; calculate albumin adjustment only with a locally accepted formula and use ionised calcium when correction is unreliable. Vitamin D deficiency is common in many Indian cohorts and can raise PTH or mask hypercalcaemia, but prevalence varies and deficiency must be measured rather than presumed. Repletion may reveal primary disease, so plan repeat calcium instead of declaring cure from a falling PTH.
Access to PTH assays, reliable 24-hour urine collection, DXA at the distal radius, renal imaging, genetic testing and high-volume parathyroid surgery is uneven. A staged pathway can confirm repeated biochemistry locally, correct modifiable secondary causes, document stone or fracture history and then refer before expensive localisation. Urine calcium interpretation should include creatinine adequacy, diet, thiazides, vitamin D and eGFR. Genetic testing is most valuable when it will change surgery or family counselling.
Experienced bilateral exploration remains an option when localisation is discordant or unavailable; imaging availability should not redefine the indication. Patients may receive high-dose over-the-counter vitamin D, calcium combinations or herbal products, so ask to see packets and doses. Costs, travel and postoperative calcium monitoring belong in shared decisions. India-specific outcome evidence is heterogeneous, and this guide does not claim one nationwide pathway or uniform availability. Institutions should audit persistent hypercalcaemia follow-up, FHH exclusion, surgical volume, cure, hypocalcaemia and loss to care.
NMC Competency Mapping
Hyperparathyroidism integrates physiology of calcium sensing and PTH secretion, biochemistry of calcium, phosphate and vitamin D, medicine assessment of hypercalcaemia and CKD, radiology of stones and skeletal disease, and surgery of the parathyroid glands. The NMC 2024 curriculum should be mapped locally to the applicable endocrine, renal, metabolic bone and neck-surgery competencies; code numbering can differ between compendium versions, so a faculty ledger must verify the exact code rather than attach an invented identifier. The educational outcome is safe reasoning across disciplines, not recall of a scan.
A learner should interpret paired calcium and PTH, explain why a reference-range PTH is abnormal during hypercalcaemia, distinguish primary from secondary and tertiary disease, and recognise PTH-independent hypercalcaemia. They should identify vitamin D and renal confounding, calculate or interpret urinary calcium clearance with its limitations, and explain why FHH changes the operative decision. They should assess stone, renal and skeletal criteria and distinguish diagnostic tests from localisation tests.
Clinical skills include a focused history, hydration and neuromuscular assessment, medicine reconciliation, clear unit-aware handover and counselling about surveillance or referral. Exam and simulation tasks may ask the learner to prioritise emergency hypercalcaemia care or present a surgical referral. Independent cinacalcet, antiresorptive or perioperative calcium prescribing remains beyond unsupervised undergraduate practice. This draft is has been reviewed by the MedNext Clinical Team and does not confer competence or replace institutional pathways.
Key Exam Pearls for NEET PG
Primary hyperparathyroidism produces hypercalcaemia with raised or inappropriately normal PTH. A suppressed PTH points away from primary disease. Classical phosphate is low or low-normal, but renal function, diet and treatment modify it. Secondary hyperparathyroidism usually has normal or low calcium because PTH is responding to CKD, vitamin D deficiency or impaired calcium availability. Tertiary hyperparathyroidism is autonomous secretion after longstanding secondary stimulation and may cause high calcium. Normocalcaemic primary disease requires exclusion of CKD, vitamin D deficiency, malabsorption, low intake and drug effects.
FHH is commonly autosomal dominant, mild and hypocalciuric. A calcium-to-creatinine clearance ratio below 0.01 supports FHH, but overlap means it is not a perfect genetic test. Do not send a patient to surgery on this ratio alone. Parathyroid imaging localises an abnormal gland for an operation; it does not establish biochemical disease. Ultrasound and sestamibi are common first-line localisation methods, with additional imaging reserved for selected discordant, ectopic or reoperative cases.
Definitive treatment is parathyroidectomy. High calcium, age below 50, renal impairment, stones or nephrocalcinosis, hypercalciuria, osteoporosis or vertebral fracture are key guideline indications in asymptomatic disease. Cinacalcet mainly lowers calcium; bisphosphonates mainly protect bone. Sudden symptomatic severe hypercalcaemia needs monitored hydration and urgent specialist treatment. Hungry bone syndrome after surgery causes prolonged hypocalcaemia from rapid skeletal uptake and requires active biochemical surveillance.
Frequently Asked Questions
Can parathyroid hormone be normal in primary hyperparathyroidism?
Yes. When calcium is high, normal physiology should suppress PTH. A value within the laboratory reference interval can therefore be inappropriately non-suppressed and support primary hyperparathyroidism after the calcium result is confirmed and FHH, medicines, CKD and other confounders are addressed. Interpretation requires a paired calcium and PTH, not two unrelated specimens.
How is familial hypocalciuric hypercalcaemia distinguished from primary hyperparathyroidism?
FHH is suggested by lifelong mild hypercalcaemia, affected relatives and low urinary calcium. A calcium-to-creatinine clearance ratio below 0.01 supports it, but CKD, vitamin D deficiency, thiazides, low calcium intake and collection error can produce a similar result. Borderline or high-stakes cases need specialist interpretation and sometimes CASR-pathway genetic testing before surgery.
Why is parathyroid imaging not used to diagnose hyperparathyroidism?
The diagnosis is biochemical, based on calcium-PTH physiology and exclusion of alternatives. Ultrasound, sestamibi and other imaging are localisation studies used to plan an operation after a surgical indication has been established. A negative scan does not exclude primary hyperparathyroidism, and a positive scan can be incidental or misleading if the biochemistry is wrong.
What follow-up is needed when primary hyperparathyroidism is not operated on?
Follow-up should specify interval calcium and renal assessment, symptoms of stones or hypercalcaemia, bone-density surveillance and reconsideration of surgery if calcium rises, kidney function declines, a stone or fracture occurs, or bone density worsens. Vitamin D and calcium intake need supervised optimisation. Medical therapy is chosen for a defined calcium or bone goal and does not eliminate surveillance.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic